tbuckley/cabot-search huggingface dataset:
Reply to ‘Machine learning detection of obstructive hypertrophic cardiomyopathy using a wearable biosensor’
Authors: Reinier van Mourik, Onur Dur, Stephen B. Heitner, Charles Wolfus, Eric M. Green, Marc J. Semigran
Journal: npj Digital Medicine (2019)

We thank Dr. Ueno for the interest in our article.In reply to his statistical concerns about the execution of the Leave-One-Group-Out cross-validation (LOGO CV) and its interpretation, we believe that the brevity of our explanation of the nested cross-validation procedure may have caused confusion, and we offer the following clarification regarding the number of CV folds and the inclusion of all 82 patients in the confusion matrix.We evaluated our classifier using nested cross-validation, 1 where the hyperparameters in each of the 82 LOGO CV folds were selected by 68-fold random patient split CV (68 folds were used to balance statistical precision and hardware efficiency).The LOGO CV method refers to the exclusion of a group of recordings from one patient.That is, for each of the 82 patients, we trained the classifier on the other 81 patients' recordings and evaluated it subsequently on the excluded patient's recordings; thus, the LOGO CV ran 82 folds.To ensure that the excluded patient is entirely new to the classifier, hyperparameter tuning must also exclude the patient.Thus, in each LOGO fold, hyperparameter tuning by cross-validation is performed on the 81-patient training set.This nested CV performs 68 folds of splitting 81 patients randomly into training (70%) and testing (30%) cohorts solely to select LOGO-fold-specific hyperparameters.These are then used during training of the classifier on the 81 patients, which is in turn used to classify the excluded patient's recordings.Since all of a patient's recordings are evaluated by an instance of the classifier that has never seen the patient, all recordings of all patients can be included in the final confusion matrix.By using nested cross-validation we have striven to prevent overestimating the model's performance.A larger study, as Dr. Ueno suggests, can further validate these results.To correct the results reported on Page 2, we would like to note that out of 64 volunteers, the automated beat detection quality control algorithm identified the PPG recordings in one subject to be technically inadequate.Therefore, the model correctly classified 18/19 patients with oHCM and 62/63 healthy volunteers (80/ 82 subjects total, 98% accuracy) as illustrated in Fig. 1d.
Contents
Authors: Leslie Klevay, Chirag Mandavia, Lakshmi Pulakat, Vincent Demarco, James Sowers, Nadeem Mohammed, Lihua Tang, Anisa Jahangiri, Willem De Villiers, Erik Eckhardt, Pauliina Utriainen, Saila Laakso, Jarmo Jääskeläinen, Raimo Voutilainen, Katharine Backhouse, Ivana Sarac, Fariba Shojaee-Moradie, Michael Stolinski, M Robertson, Gary Frost, Jimmy Bell, E Thomas, John Wright, David Russell-Jones, A Umpleby, Martijn Spoelstra, Andrea Mari, Marijke Mendel, Edward Senga, Patrick Van Rheenen, Theo Van Dijk, Dirk-Jan Reijngoud, Remco Zegers, Tom Heikens, Robert Bandsma, Jeremy Krebs, Amber Parry-Strong, Mark Weatherall, Richard Carroll, Michelle Downie, Andrew Krentz, Denise Von Mühlen, Elizabeth Barrett-Connor, Robert Disilvestro, Elizabeth Joseph, Wenyi Zhang, Adrienne Raimo, Young Kim, Rita Gómez-Díaz, Juan Talavera, Elsy Pool, Francisco Vianney Ortiz-Navarrete, Fortino Solórzano-Santos, Rafael Mondragón-González, Adan Valladares-Salgado, Miguel Cruz, Carlos Aguilar-Salinas, Niels Wacher, Kevin Comerford, Rogelio Almario, Kyoungmi Kim, Sidika Karakas, Unab Khan, Dan Wang, Maryfran Sowers, Peter Mancuso, Susan Everson-Rose, Philipp Scherer, Rachel Wildman, Natalia Poliakova, Jean-Pierre Després, Jean Bergeron, Natalie Alméras, Angelo Tremblay, Paul Poirier, Nicole Crisp, Paul Fournier, Melissa Licari, Rebecca Braham, Kym Guelfi, Mariëlle Engelen, Erica Rutten, Carmen De Castro, Emiel Wouters, Annemie Schols, Nicolaas Deutz, Lorena Sarati, Carla Martinez, Nicolás Artés, Noelia Arreche, Juan López-Costa, Ana Balaszczuk, Andrea Fellet, Nobuya Ogawa, Makoto Ito, Hideki Yamaguchi, Tetsuya Shiuchi, Shiki Okamoto, Korekiyo Wakitani, Yasuhiko Minokoshi, Masamitsu Nakazato, Qiang Mei, Daijun Zhou, Jialong Han, Hai Lu, Bo Tang
Journal: Metabolism (2012)
Abstract 1364: A Non-Small Cell Lung Cancer Reference Material
Authors: Farol L. Tomson, Catherine Huang, Omo Clement, Russell Garlick, Bharathi Anekella
Journal: Cancer Research (2019)

Abstract Lung cancer is the leading cause of cancer death in the United States as well as globally. The major diagnosis (~85%) of lung cancer patients is non-small cell lung carcinoma (NSCLC). About 10-50% of NSCLCs have several activating EGFR driver mutations which have been clinically validated as therapeutic biomarkers for anti-EGFR drugs. Identifying these driver mutations through liquid biopsies is a promising alternative to traditional biopsies; however, the precision of mutation analysis for some of these targets, e.g., T790M, especially in advanced-stage metastatic NSCLC patients remains a challenge. To address this, we developed a platform of single and low complexity, highly patient-like circulating tumor DNA (ctDNA) EGFR reference standards designed for PCR assays that are used for EGFR-based patient testing. We mixed genomic DNA from the highly characterized human cell line (GM24385) with four synthetic EGFR variant-containing DNA sequences: T790M, L858R, G719S, and an ex19 deletion, in both individual and combined format. Using digital PCR we were able to precisely blend the material at the defined variant allele frequencies of 1% and 0.1%. In addition, wild-type reference material without any synthetic EGFR variants was also created as a comparable negative control. The materials were size-selected (160-170bp) after fragmentation for more patient-like ctDNA size characteristics. After size-selection the material is further refined to improve conversion efficiency. In order to make the material comparable to native ctDNA, such as that isolated from cancer patients, we encapsulated the DNA fragments into a synthetic plasma matrix. The process of DNA size selection followed by encapsulation and formulation into a synthetic plasma matrix enhances the commutability of these reference standards and improves the long-term stability of the samples to at least two years. The allele frequencies of the reference materials were confirmed by both dPCR and NGS. The Archer Reveal ctDNA 28 Kit was used for NGS library preparation while an Illumina MiSeq, using v2 (2x150 bp) PE chemistry reagents, was used for sequencing. Additional evaluation of these materials was conducted by laboratories that provide EGFR RT-PCR tests for patient anti-EGFR therapy stratification. The data from the dPCR, NGS and RT-PCR assays were comparable and highlight the broad compatibility of these EGFR ctDNA reference standards on a variety of assay testing platforms for NSCLC. Citation Format: Farol L. Tomson, Catherine Huang, Omo Clement, Russell Garlick, Bharathi Anekella. A Non-Small Cell Lung Cancer Reference Material [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1364.
Clinical Aspects of Neuroimmunology.
Journal: Annals of Internal Medicine (1980)

narrow-spectrum drugs does not convey the fact that co-trimoxazole or amoxycillin are the drugs of choice in the treatment of most chest infections in patients with sex-linked or late-onset hypogammaglobulinaemia.The suggestion that pentamidine might be used in the prophylaxis of Pneumocystis carinii pneumonia is wrong.In fact, co-trimoxazole is the only drug suitable for prophylaxis and is the drug of choice for treatment.The section on malignancy makes the important point that the raised incidence occurs mainly in patients with ataxia telangiectasia and Wiskott-Aldrich syndrome.British experience does not bear out the comment that 6-9 % of patients with sex-linked hypogammaglobulinaemia develop tumours.The old WHO term of 'common variable immunodeficiency' has now been changed to 'varied immunodeficiency.'The reviewer believes that most of the patients previously described under this heading should now be described under the term 'late-onset hypogammaglobulinaemia.'This refers to patients with hypogammaglobulinaemia of unknown aetiology affecting IgG and IgA and usually IgM, which starts after the first 2 years of life with a normal percentage of T cells by E rosetting.Some of the conclusions are debatable.Gammaglobulin injections have been disappointing in the treatment of selective IgA deficiency, This removes much of the value in preparing gammaglobulin for injection which is free from IgA.
INTRATRACHEAL INJECTIONS.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lipoproteins and atherogenesis. Current concepts
Authors: D. Steinberg
Journal: JAMA (1990)

TODAY there is no longer any doubt about the causative relationship between hypercholesterolemia and premature atherosclerosis. The National Institutes of Health Consensus Conference on Lowering Blood Cholesterol Levels<sup>1</sup>and the National Cholesterol Education Program that grew out of it<sup>2</sup>were the culmination of many years of experimental and clinical research, including, importantly, a number of positive intervention trials that brought to a close the so-called Cholesterol Controversy,<sup>3</sup>ie, the controversy as to the importance of hypercholesterolemia as a<i>causative</i>factor in coronary heart disease. Intensive lipid-lowering regimens have been shown not only to slow the progression of coronary atherosclerosis and reduce the risk of coronary events,<sup>4</sup>but even in some cases to lead to absolute regression.<sup>5</sup>Best medical practice now calls for appropriate treatment of hypercholesterolemia, and detailed guidelines for treating it are available.<sup>2,6</sup> If we are, then, committed in any case to such
Programs in Medical Education Sponsored by Government Agencies
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Otospongiosis begins to yield its secrets
Authors: P. Gunby
Journal: JAMA (1979)

About one in ten Americans, most often an adult of Caucasian ancestry, experiences a strange, insidious, spongy bony overgrowth called otosclerosis or otospongiosis. It starts in the middle ear and in about 80% of cases affects both ears, sometimes impairing hearing and even the vestibular mechanism. Some aspects of this disorder have been recognized for more than 250 years. For example, the early 18th-century anatomist Antonio Maria Valsalva observed that spongification can immobilize the stapes by creating a bony bridge to the fenestra vestibuli (oval window), into which the stapes' footplate fits. Nevertheless, many questions still are unanswered, and only now is the disorder beginning to yield its secrets. This became clear recently at a state of the art conference on labyrinthine otospongiosis, conducted in Lake Bluff, Ill, by the National Hearing Association and chaired by Jack L. Pulec, MD, Los Angeles. Data reported suggest that the disorder is more
A poetic link to art of medicine
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Interim Guidelines for Prevention and Control of Staphylococcal Infection Associated With Reduced Susceptibility to Vancomycin
Journal: JAMA (1997)

Staphylococci are one of the most common causes of community- and hospital-acquired infection. In many U.S. hospitals, strains of staphylococci (i.e., Staphylococcus aureus or coagulase-negative staphylococci) are resistant to all available antimicrobials except vancomycin. Rare cases of infection in the United States (1) have been caused by coagulase-negative staphylococci with reduced susceptibility to vancomycin (minimum inhibitory concentration [MIC] > or = 8 microg/mL)(2).
Comment
Authors: Philip Rubin
Journal: JAMA (1965)

The need for careful studies as herein presented demonstrates the ability of irradiation to sterilize pelvic lymph nodes. This is an area of much misconception since the radioincurability of metastatic nodes has often been equated to, or measured by, patient deaths. As metastatic nodal disease is usually a sign of moderately advanced cancer, local control of the primary and regional nodes may often be achieved without halting dissemination. A patient, therefore, may not be treated successfully with metastatic nodes because of death due to distant spread. The failure is not simply that of the inadequacy of local therapy, be it surgery or irradiation, but local therapy is inadequate in that it does not encompass all the disease. The need to determine the relative value of surgery and radiotherapy in controlling metastatic nodes is an important question to explore. The combining of two full courses of therapy such as radical surgery
Assessment of the Health Effects of Atmospheric Sulfur Oxides and Particulate Matter: Evidence from Observational Studies
Authors: James H. Ware, Lawrence A. Thibodeau, Frank E. Speizer, Steven Colome, Benjamin G. Ferris
Journal: Environmental Health Perspectives (1981)

Steadily rising energy costs have increased the need for reliable information on the health effects of atmospheric sulfur oxides and particulate matter. Because ethical and practical considerations limit studies of this question under controlled conditions, observational studies provide an important part of the relevant information. This paper examines the currently available epidemiologic evidence from population studies of the health effects of these pollutants. Nonexperimental studies also have important limitations, including the inability to measure accurately the exposure burden of free living individuals, and the potential for serious confounding by other factors affecting health. We begin with a discussion of some of these methodologic issues. The evidence is then reviewed, first in association with fluctuations in 24 hr mean concentration of sulfur oxides and particulate matter, and then in association with differences in mean annual concentration. In the last section, this evidence is summarized and used to approximate the exposure-response relationship linking pollutant concentrations with mortality and morbidity levels.
Medicolegal rounds. Leading cases
Journal: JAMA (1975)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
What's ahead in the treatment of hemophilia
Authors: Francesco Rodeghiero
Journal: HemaSphere (2018)

Hematology Project Foundation, Vicenza, Italy This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CCBY-NC-ND), which allows third parties to download the abstracts and share them with others as long as they credit the author and the abstract book, but they cannot change the content in any way or use them commercially. http://creativecommons.org/licenses/by-nc-nd/4.0
Exercise-related hematuria. Findings in a group of marathon runners
Authors: A. J. Siegel
Journal: JAMA (1979)

Sequential urine specimens were obtained from 50 marathon runners before, immediately after, and on three successive days following a marathon race. All prerace samples were normal, but nine (18%) of the 50 postrace urinalyses showed gross (one specimen) or microscopic (eight specimens) hematuria. No formed elements other than RBCs were seen, and all abnormalities cleared by 48 hours. Exercise-related hematuria appears to be a frequent, self-limited, and benign condition. Physicians should be aware of its occurrence and reserve extended testing for cases in which abnormalities persist beyond 48 to 72 hours. (<i>JAMA</i>241:391-392, 1979)
Abstract 595: A cell-permeant amiloride derivative induces caspase-independent, AIF-mediated programmed necrotic death of breast cancer cells.
Authors: Leonardo J. Leon, Nagarekha Pasupuleti, Fredric Gorin, Kermit Carraway
Journal: Cancer Research (2013)

Abstract Amiloride is a potassium-sparing diuretic that has been used as an anti-kaliuretic for the chronic management of hypertension and heart failure. Several studies have identified a potential anti-cancer role for amiloride, however the mechanisms underlying its anti-tumor effects remain to be fully delineated. Our group previously demonstrated that amiloride triggers caspase-independent cytotoxic cell death in human glioblastoma cell lines but not in primary astrocytes. To delineate the cellular mechanisms underlying amiloride's anti-cancer cytotoxicity, cell permeant and cell impermeant derivatives of amiloride were synthesized that exhibit markedly different potencies in cancer cell death assays. Here we compare the cytotoxicities of 5-benzylglycinyl amiloride (UCD38B), and its free acid 5-glycinyl amiloride (UCD74A) toward human breast cancer cells. UCD74A exhibits poor cell permeability and has very little cytotoxic activity, while UCD38B is cell permeant and induces the caspase-independent death of proliferating and non-proliferating breast cancer cells. UCD38B treatment of human breast cancer cells induces autophagy, reflected in LC3 conversion, however this does not appear to be the cause of cell death. Electron microscopy reveals that UCD38B induces a dramatic swelling of intracellular organelles such as the endoplasmic reticulum and mitochondria. Surprisingly UCD38B, but not UCD74A, induces efficient AIF translocation from the mitochondria to the nucleus, and AIF function is necessary for the efficient induction of cancer cell death. Our observations indicate that UCD38B induces programmed necrosis through AIF translocation, and suggest that cytosolic accessibility may facilitate drug action. Citation Format: Leonardo J. Leon, Nagarekha Pasupuleti, Fredric Gorin, Kermit Carraway. A cell-permeant amiloride derivative induces caspase-independent, AIF-mediated programmed necrotic death of breast cancer cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 595. doi:10.1158/1538-7445.AM2013-595 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.